Sentences with phrase «tumor immunology program»
In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
https://wistar.org/
Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center
Dr. Antoni Ribas is the director of the Tumor Immunology Program at the University of California, Los Angeles Comprehensive Cancer Center, and the chair of the Melanoma Committee at SWOG.
«What he showed us is turning the immune system on isn't enough; the crucial step is to make sure it doesn't turn itself off,» says Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center.
He actively participates in the Host - Tumor Interactions and Tumor Immunology programs.
Not exact matches
«We had a hypothesis about how these treatments would work together, and when we did biopsies of patients» tumors we found that they were cooperating in just the way we thought they would,» says lead author Antoni Ribas, director of the Immunology Program at the UCLA Jonsson Comprehensive Cancer Center.
«Pancreatic cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Lprogram nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU LProgram at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone.
Tumors are home to diverse immune cell types, some of which remain much less explored than T cells and could also control cancer progression» says Mikael Pittet, PhD, director of the Cancer Immunology Program in the MGH Center for Systems Biology and senior author of the Science paper.
«Our research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states,» says Robert Rickert, Ph.D., director of the Tumor Microenvironment and Cancer Immunology Program at Sanford Burnham Prebys Medical Discovery Institute (SBP).
«We have experiments in mice that show that the combined use of PD - 1 antibody and poly - IC is synergistic for the recognition of tumors and an antitumor response mediated by T - cells,» says Dr. Esteban Celis, co-leader of the Cancer Immunology, Inflammation and Tolerance program at the Georgia Cancer Center at Augusta University.
Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.
Cancer Research Institute inaugurates its Investigator Award Program for junior faculty members working in immunology and tumor immunology.
Co-Leader, Host - Tumor Interactions Research Program Louise B. McGavock Professor of Pathology, Microbiology and Immunology Assistant Vice Chancellor for Integrative Diagnostics
Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.
Michel Detheux, iTeos» Chief Executive Officer added, «The progress of our adenosine A2A antagonist program demonstrates how we can rapidly apply our expertise in medicinal chemistry, tumor immunology and translational medicine to advance candidates toward clinical development.»
CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.